P-selectin glycoprotein ligand-I (PSGL-1) is a high-affinity counterreceptor for P-selectin on myeloid cells and activated T-cells. In addition, PSGL-1 can serve, both in vitro and in vivo, as an E-selectin ligand. Appropriate glycosylation of PSGL-1 is crucial for binding to P-selectin. Functional PSGL-1 is known to bear sialyl lewis X (SLe') or a closely related oligosaccharide. In this study, we show that Chinese hamster ovary (CHO) cells expressing PSGL-1 and fucosyltransferase show a dramatic increase in binding to P-selectin when transfected with "core2" transferase, the enzyme that -SELECTIN GLYCOPROTEIN ligand-1 (PSGL-1) is a P human leukocytic cell surface mucin originally identified as a high-affinity ligand for P-selectin (CD62P) by a novel expression cloning strategy involving cotransfection of COS cells with a myeloid cDNA library and a sialyl lewis X @LeX)-forming fucosyltransferase.' This and other ~t u d i e s~.~ have shown that PSGL-1 is the major glycoprotein ligand for P-selectin isolated from neutrophils and HL-60 cells. The gene for PSGL-1 has been mapped to human chromosome 12 and contains a single 9-kb intron in the 5'-untranslated r e g i~n .~
P human leukocytic cell surface mucin originally identified as a high-affinity ligand for P-selectin (CD62P) by a novel expression cloning strategy involving cotransfection of COS cells with a myeloid cDNA library and a sialyl lewis X @LeX)-forming fucosyltransferase.' This and other ~t u d i e s~.~ have shown that PSGL-1 is the major glycoprotein ligand for P-selectin isolated from neutrophils and HL-60 cells. The gene for PSGL-1 has been mapped to human chromosome 12 and contains a single 9-kb intron in the 5'-untranslated r e g i~n .~
The gene for PSGL-I encodes a type-1 transmembrane protein of 402 residues that is secreted as a disulfide-linked homodimer with an apparent molecular mass of =220 kD. PSGL-1 is widely distributed on leukocytic cells but is functional as a P-selectin counterreceptor only on myeloid cells, stimulated T-cells, and possibly platel e t~.~. ' PSGL-I appears to serve as the physiological counterreceptor for P-selectin. Antibodies to PSGL-1 block myeloid cell adhesion to P-selectin both under static and shear flow
In addition, the P-selectin-dependent adhesion of specific lymphocytic cell populations has also been reported to be blocked by anti-PSGL-1 antibodies.'" PSGL-1 has also been shown to bind to E-selectin in a calciumdependent manner' and has been described as the major high-affinity ligand for E-selectin on myeloid cells." Thus, PSGL-1 seems to play a central role in P-and E-selectinmediated adhesion of leukocytes to activated endothelia or platelets.
Recently, critical structural features of PSGL-1 required for high-affinity binding to P-selectin have been identified. Two components, one protein and the other carbohydrate, appear to define the high-affinity P-selectin-binding epitope on PSGL-I . Two lines of evidence support the existence of a protein determinant. First, mutational analysis of PSGL-1 has shown that a sulfotyrosine-containing anionic fragment, located within the first 19 residues of PSGL-I, is essential for high-affinity P-selectin Second, a novel metalloproteinase from cobra venom has been shown to selectively cleave the amino terminal 10 residues from mature PSGL-1 and to completely ablate P-selectin binding." Moreover, this same study showed that an antibody raised against residues 1-15 of mature PSGL-1, but not one raised against residues 9-23, inhibits P-selectin binding.
The presence of oligosaccharides such as SLeX and related structures have also been shown to be critical for binding to P-~electin.'~,~' Sako et al' showed that cotransfection of COS cells with both PSGL-1 and a fucosyltransferase capable of synthesizing SLeX is required for PSGL-1 binding to P-and E-selectin. The extracellular domain of PSGL-I contains three potential sites of N-glycosylation and numerous potential sites of 0-glycosylation. Previous studies have shown that N-glycosidase digestion of PSGL-1 does not alter binding to P-selectin.'," Similarly, point mutation(s) of N-linked glycosylation sites of PSGL-I failed to change binding to P-selectin suggesting that N-linked glycans of PSGL-1 are not necessary for binding to P-selectin." The most definitive evidence for the importance of 0-linked glycans comes from the study that used the minimal P-selectin-binding domain of PSGL-1, the N-terminal 19 amino acids. After mutagenesis of the single 0-linked glycosylation site used in this domain, P-selectin binding is lost." However, little is known about the structural feature(s) of 0-linked glycans required for high-affinity binding of PSGL-1 to P-selectin. Recently, Moore et ai" have shown that the 0-linked oligosaccharides of PSGL-1 isolated from human neutrophils are composed, at least in part, of poly-N-acetyllactosaminylated chains that are sialylated and fucosylated. Although no direct evidence was presented that such 0-glycans are required for P-selectin binding, the observation is nonetheless of interest because previous work" has shown that CD43, a major leukocytic sialoglycoprotein, presents SLeX on branched 0-linked polylactosamine structures. Biosynthesis of such branched 0-glycans requires the action of a specific posttranslational processing enzyme, the "core2" GlcNAc(P 1,6)transferase.
In the present study, we provide direct evidence that elabo- For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From ration of 0-linked oligosaccharides by core2 GlcNAc(P 1,6)-transferase is crucial for high-affinity binding of PSGL-1 to P-selectin.
MATERIALS AND METHODS

Reagents.
Benzamidine, leupeptin, phenylmethylsulfonylfluoride (PMSF), N-acetylglucosamine (GlcNAc), N-acetyllactosamine (LacNAc), HEPES, and sodium phosphate were purchased from Sigma (St Loius, MO). Random prime labeling kit was from Pharmacia (Uppsala, Sweden). 35S-methionine, 3H-thymidine, and 3H-glucosamine-HC1 were obtained from DupontNEN (Boston, MA). Lipofactin, (3418, Opti-MEM and methionine-free media were from GIBCOlBRL (Gaithersburg, MD). Restriction enzymes were from New England Biolabs (NEB; Beverly, MA). Murine IgG and Human IgG were from Sigma. Fluorescein isothiocyanate (FITC)-conjugated protein A was obtained from Zymed (San Francisco, CA), and protein A sepharose was purchased from Pharmacia. Sialyl Lewis x, Lewis x, lacto-N-tetraose (LNT), and lacto-N-fucopentaose (LNFPIII) were from Oxford Glycosystems (Abington, UK). Galp 1 -3GalNAc was produced from the disialylated parent (Di-sialyl-tetraose; Oxford Glycosystems) by neuraminidase digestion.
A polyclonal rabbit antibody Rb3443 and an anti-PSGL-I murine monoclonal antibody (MoAb) PSL275 (IgG, ) were raised against a synthetic peptide comprising the first 15 amino acids of the mature (paired basic amino acid converting enzyme [PACE]-cleaved) N-terminus of PSGL-1. Rb3443 and a monoclonal anti-CD43 antibody (Becton Dickinson, Mountain View, CA) were covalently coupled to immobilized Protein A resin via the manufacturer's (Pierce, Rockford, IL) instructions at concentrations of 2 mL/mL resin and 1 mglmL resin, respectively. An anti-SLeX MoAb, CSLEX-1, (IgM) was obtained from the American Type Culture Collection (Rockville, MD) and used as ascites. Antibodies raised against Pselectin (HPDG 2/3, HPDG2/1) and E-selectin (HEL3l2, HEIAII) have been described previously.' Goat antihuman IgG was purchased from Jackson Immunoresearch Laboratories (West Grove, PA).
Core2-recipient Chinese hamster ovary (CHO) cell line (3.4B) expressing a( 1,3/1,4) fucosyltransferase (FUC-TIII)'~ and PSGL-1 was grown in alpha media with 10% fetal calf serum, 2 mmol/L glutamine, and 100 nmoVL methotrexate. Transfectants expressing core2 enzyme (3.4B + C2) were grown in the same media with 1 mg/mL (3418. U937 cells were propagated in RPMI with 10% fetal calf serum.
Core2 cDNA was isolated from a previously described HL60 cDNA library' as follows. Based on the published sequence of core2;' two oligos designated as Core2-1 (sense 5' GCTCTAGAATGCTGAGGACGTTG CTGCGAAG 3') and Core2-2 ( a n t i s e n s e ' GGAGACATTAAAACACTGACC GAATTCACA 3') were used to amplify core2 cDNA from t h e L 6 0 cDNA library. The purified polymerase chain reaction (PCR) product was used as a probe to screen the library and isolate core2 cDNA clones by standard molecular biology techniques. In summary, about 40,000 clones from the positive pool were plated on LB agar plates. Colonies were lifted on nitrocellulose filter and hybridized with '*P-radiolabeled PCR fragment at 42°C in hybridizing buffer (50% formamide, 5X standard saline citrate [SSC], 5 x Denhardt's solution, and 100 pg/mL salmon sperm DNA). Filters were washed in I X SSC and 0.2% sodium dodecyl sulfate (SDS) buffer at 54°C. Three positives were isolated and purified by replica plating. The clone pMTCore2, containing an insert of about 2.0 kb, was sequenced and found to be identical to the published sequence."
Parental CHO-DUKX cells were cotransfected with PSGL-I (pPL85) and Fuc-TI11 (PED Fuc-TIII) by the calcium phosphate method as described previously.22
Antibodies.
Cell lines.
Isolation of core2 cDNA.
Transfection of DNA in CHO ceifs.
In brief, IO6 cells were plated and, 24 hours later, were treated with DNA-calcium phosphate complex. The following day, cells were washed and fed with growth media. After 24 hours, cells were trypsinized and distributed into five dishes in complete alpha media. Approximately 2 weeks later, stable colonies were isolated and grown in methotrexate. One of the clones, 3.4B, was grown in 100 nmollL methotrexate and used as a recipient cell line for the core2 gene.
Core2 cDNA (pMTCore2) was cotransfected with pMT4neo into 3.4B cells by liposome methods as per the manufacturer's (GIBCO) instructions. Transfectants were selected for G418 (1 mglmL) resistance, and the stable clone 3.4B + C2 was isolated.
( D l -6)GlcNAc transferase (core2) enzyme assay. The Core2 enzyme assay was performed essentially as described by Higgins et Briefly, the reaction mixture (50 pL) contained 50 mmol/L sodium cacodylate (pH, 6.7). 0.1 % Triton X-100,0.1% bovine serum albumin (BSA), 0.1 mom GlcNAc, 10 nmol uridine diphosphate (UDP)-('H) GlcNAc (=20,000 CPM/nmol), and 2 mmol/L pDGal( 1 -3)Da-GalNAc-p-nitrophenol (Sigma) as a substrate. After adding I O pL of cell lysate (30 to 100 pg protein), the reaction mixture was incubated at 37°C for 1 hour. The reaction was terminated with 1 mL of ice-cold water and processed on a C18 Sep-Pak column (Waters-Millipore, Bedford, MA). After washing the column with 5% acetonitrile, the product was eluted with 20% acetonitrile and counted.
In each case, the protein concentration was determined with a BCA assay (Pierce). Control reactions carried no acceptor. Specific activity was determined and expressed as picomoles per minute per milligram.
Binding of CHO cells to immobilized (A) P-selectin or (B) Eselectin.
A solution of goat antihuman IgG antibody (2.0 pg/mL) in 50 mmoVL Tris buffer (pH, 9.5) was coated on 48-well nontreated (Costar Cat. no. 3547; Costar, Cambridge, MA) plates and incubated at 4°C for 5 hours. After washing the plates with Hank's Balanced Salt Solution (HBSS) buffer, either P-selectidIgG chimera (Lecyl; 0.1 pg/mL) or E-selectin/IgG chimera (Lecy2; 5 pg/mL) was added and incubated overnight at 4°C. The following day, plates were blocked with 3 mg/mL BSA in phosphate-buffered saline (PBS) at 4°C for 2 to 3 hours. Cells were labeled with 'H-thymidine for 24 hours and then removed with 5 mmol/L EGTA. Cells were washed with serum-free alpha media 3 to 4 times and resuspended at IO6 cellslml. An aliquot (200 pL) of cell suspension was added to each well and incubated at room temperature for 12 minutes. Unbound cells were aspirated, and wells were washed 3 to 4 times with serumfree alpha media. Bound cells were removed with EGTA and counted in a scintillation counter.
FITC-conjugated protein A was precomplexed with human IgG or P-selectiniIgG chimera (Lecyl) at a ratio of 1:5 at 4°C for 16 hours. Cells were removed with 5 mmoU L EGTA and washed with fluorescence-activated cell sorting (FACS) buffer (alpha media with 2% fetal calf serum and 0.02% sodium azide) 3 times. Approximately lo6 cells per sample were incubated with F'ITC-conjugated protein A-human IgG or -Lecy 1 complexes at 4°C for 30 minutes. Treated cells were washed with FACS buffer and fixed in 2% formaldehyde solution in PBS. For PSGL-I and SLeX staining, IO6 cells were incubated with 50 pL of PSL275 (1 8 pg/mL) or CSLEX-I (50 pg/mL) followed by 50 pL of FITCconjugated goat antimurine IgGflgM (150 dilution). As a control, murine IgG or IgM was used at a similar concentration. After each 30-minute incubation, cells were washed with FACS buffer 3 times. Cells were fixed in 2% formaldehyde solution in PBS and were analyzed on Becton Dickinson FACScan flow cytometer.
Immunoprecipitation and SDS-polyacrylamide gel electrophoresis (SDS-PAGE) studies. Cells were labeled with 'H-glucosamine (200
Flow cytometric analysis.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From pCi/mL) for 2 days and then lysed in extraction buffer (Tris-buffered saline [TBS] buffer containing I% Triton X-100, 0.02% NaN', 2 mmol/L EDTA, 1 m m o m PMSF, 1 mmol/L benzamidine, I mmol/ L ethylmaleimide, 0.1% aprotinin, and 0.5 pg/mL leupeptin). Protein A beads were precomplexed with either P-selectinlIgG chimera (Lecyl) or anti-PSGL-1 antibody (Rb3443) as describedpreviously. ' The lysate was diluted with immunoprecipitation (IP) buffer (TBS buffer with 5 mg/mL BSA, 2 mmol/L CaCI,, 0.02% NaN,) and centrifuged at 15,OOOg for 15 minutes. The supematant was incubated on ice for 2 hours with either Lecyl or Rb3443 precomplexed with Protein A beads. Beads were washed 3 times with IP buffer and 3 times with IP buffer containing 0.5% Triton X-100. In the case of Rb3443, beads were resuspended directly into the sample buffer, whereas Lecyl-bound material was eluted from beads with TBS containing 5 mmol/L EDTA and 5 mmol/L EGTA. The eluate was divided into two equal aliquots. One aliquot was precipitated with 20% trichloroacetic acid (TCA), and samples were dissolved into SDS sample buffer. The other aliquot was immunoprecipiatated with Rb3443 precomplexed with protein A beads as described above. Electrophoresis was performed on 4% to 20% Tris-Glycine gel (Novex, San Diego, CA). After electrophoresis, the gel was fixed with methanol (20%) and acetic acid (80%), treated with Enhancer (Amersham, Arlington Heights, IL), and dried at 80°C for 2 hours. The gel was exposed to Kodak X-OMAT film (Eastman-Kodak, Rochester, NY) for 4 hours. , and subjected to several cycles of probe sonication on ice. Nuclei and cell debris were removed by low-speed centrifugation, and the cell membranes were recovered from the supematant by centrifugation at 100,OOOg for 1 hour. The membrane pellet was resuspended in 1 mL (for CHO cells) or 3 mL (for U937 cells) membrane solubilization buffer (cell lysis buffer containing I % Triton X-100). Several cycles of sonication and incubation on ice were used to solubilize the membrane fractions. The insoluble fraction was removed by low-speed centrifugation.
CHO cells (3.4B and 3.4B + C2) and U937 membrane extracts were reacted with 50 p L each of Rb3443 and anti-CD43 immobilized resins, respectively, for 4 hours at 4°C with end-over-end mixing. After centrifugation and removal of the supematant, the resins were washed twice in lysis buffer containing 1% Triton X-100 and four times in MOPS buffer (10 mmol/L MOPS, 150 mmoVL NaCI, 1 mmol/L CaCI,, I mmol/L MgCl, [pH, 7.51 containing 0.05% NaN,), at which point the radioactivity of the wash supematant was reduced to background level. Elution of proteins bound to the resins was accomplished by boiling in 100 to 200 pL 0.1% SDS for 5 minutes. The supernatants were recovered, and the resins were washed with an additional 100 to 200 pL of MOPS buffer. The original supematant and washes were combined, filtered through Micropure separators (0.45 pmolL; Amicon, Danvers, MA) to remove residual resin, and then dialyzed against water using Biodialysers (Sialomed, Inc, Baltimore, MD) equipped with 25,000 molecular weight cutoff membranes at 4°C for 5 days.
Desalted, detergent-free samples of PSGL-1 and CD43 were sub-
Isolation of 0-linked glycans.
jected to 0-glycan release via mild hydrazinolysis using a GlycoPrep 1000 system (Oxford GlycoSystems) per the manufacturer's instructions. Released 0-glycans in dilute acetic acid were taken to dryness by rotary evaporation. These were resuspended in I mL water, filtered through 0.22-pmol/L syringe filters (Millex-GV; Millipore ). and redried. 0-glycans were desialylated using Clostridium perfringens neuraminidase (NEB). Glycan preparations were resuspended in 50 pL of 50 mmol/L sodium citrate (pH, 4.5) containing enzyme at 125 NEB U/digest. Digestion was performed at 37°C for 18 hours, at which point desialylation of a control sample of SLeX (100 pg) was determined to be complete. Digests were stored at 20°C. 0-glycan digests were resolved by gel-filtration high-performance liquid chromatography (HPLC) using two TSKgel G-Oligo-PW (TosoHaas, Montgomeryville, PA) columns (7.8 mm X 30 cm) connected in tandem to a Waters model 625 HPLC pump and model 490 absorbance detector. Chromatography was conducted using IO0 mmol/L ammonium bicarbonate (pH, 8) at a flow rate of 0.25 mL/ min and 60°C running temperature. Chromatographic reproducibility of 0-glycan digests was monitored by coinjection with a 5-pL standard solution consisting of 50 p g each GlcNAc, LacNAc, and LNFP 111 and detection at 214 nm. Postdetector eluates were collected as 0.5-minute fractions, and these were subjected to liquid scintillation counting (2 minutes count time).
RESULTS
Fucosyltrunsferuse activity alone is inadequate for generuting high-ufJinity P-selectin ligand in CHO cells. Previously, the human myelocytic cell line U937 has been shown to bind to P-selecth6 A shift in fluorescence intensity is observed in FACS analysis of P-selectin binding to U937 cells as shown in Fig lb. In contrast, a stable CHO cell line (3.4B) coexpressing Fuc-TI11 and PSGL-1 showed very little binding to P-selectin by FACS analysis (Fig le) , in spite of the fact that PSGL-1 is expressed on the surface of 3.4B cells at a level higher than that on U937 cells as judged by anti-PSGL-1 MoAb PSL275 (Fig l a and d) . In addition, FACS analysis with the anti-SLeX antibody, CSLEX-I , shows that the cell surface level of SLeX on 3.4B cells is similar to that on U937 cells (Fig IC and f) . Taken together, these observations suggest that a crucial posttranslational modification of PSGL-1 is absent in CHO cells but present in myeloid cells. Previous studies'.6 have suggested that PACE processing of PSGL-1 may be necessary for P-selectin binding. Importantly, the MoAb PSL275 used for FACS analysis has been shown to bind only to the PACE-processed PSGLl 6 suggesting that PACE-processed PSGL-1 is present on the surface of 3.4B cells. Therefore, alternative posttranslational modifications must be responsible for the generation of a high-affinity PSGL-I in U937 cells. Recently, Sako et all3 and others"," have shown that sulfation of critical tyrosine residues within the N-terminus of mature PSGL-1 is crucial for high-affinity binding of PSGL-1 to P-selectin. Because CHO cells are also known to sulfate tyrosine residue^,'^ we reasoned that the missing posttranslational modification was related to glycan biosynthesis, despite the fact that the 3.4B cell line was competent to synthesize SLeX. One potential missing modification was branching of 0-linked glycans, because CHO cells typically synthesize only simple core I O-glycans.2s An earlier study" has shown that the 
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Fluorescence Intensity - GlcNAc(P1,6) transferase (core2), which is required for branched 0-linked glycans, is present in both myeloid and COS cells but is absent in CHO cells. Expression of core2 is required for high-aflnity binding of PSGL-1 to P-selectin. To test our hypothesis that core2 activity is crucial for PSGL-1 functionality, the cDNA for core2 was transfected into CHO 3.4B cells, and a new stable cell line (3.4B + C2) was subsequently isolated. The level of core2 activity in 3.4B + C2 was comparable with that of COS cells (3 pmol/min/mg) but was 10-fold lower than that of U937 cells.
As shown in Fig 1, transfection of core2 transferase itself into CHO 3.4B did not alter PSGL-1 or SLeX expression as judged by FACS analysis using the MoAb PSL-275 (Fig Id  and g ) or CSLEX-1 (Fig If and i) , respectively. However, a 10-fold increase in fluorescence intensity is observed in Pselectin binding to 3.4B + C2 cells as compared with that to 3.4B (Fig le and h ).
Enhanced binding of 3.4B + C2 cells to P-selectin is also observed in a static cell binding assay. As shown in Fig 2A, the number of 3.4B + C2 cells bound to immobilized Pselectin was sixfold more than for the parental 3.4B cells. This interaction is calcium-dependent and could be abolished by a neutralizing anti-P-selectin antibody (HPDG2/3), whereas the non-neutralizing antibody HPDG 211 had no effect. As controls, CHO-DUKX cells showed no appreciable binding to P-selectin, and no binding was observed to immobilized human IgG alone. Finally, no significant binding to P-selectin was observed with CHO cells expressing Fuc-TI11 and core2 but no PSGL-1 (data not shown).
Both 3.4B and 3.4B + C2 cell lines were also tested for their ability to bind to E-selectin. As shown in Fig 2B, 3 .4B + C2 cells showed the same level of binding to E-selectin as did 3.4B cells. This result is consistent with the observation that SLex expression remains unchanged on core2 transfection, as judged by FACS analysis (Fig If and i) . This E-selectin binding was calcium-dependent and could be abrogated by a neutralizing anti-E-selectin antibody (HEL 312) but not by a non-neutralizing antibody (HEL 41 1; see Fig 2B) .
To evaluate further the effect of core2 modification on PSGL-1 binding to P-selectin, affinity-capture experiments using an anti-PSGL-1 antibody (Rb3443) and immobilized P-selectin were performed (Fig 3) . Cells were labeled with 3H-glucosamine, and membrane preparations were solubilized with Triton X-100. Equal aliquots of each membrane extract were affinity-captured with either Rb3443 or P-selectin. To confirm that the material that bound to P-selectin was indeed PSGL-1, P-selectin-bound material was eluted with EDTAEGTA and reimmunoprecipitated with anti -PSGL-1 antibody Rb3443. As shown in Fig 3, Rb3443 bound similar amounts of PSGL-1 from each transfectant (Fig 3, lane 1) . washes, bound cells were lifted with EGTA and counted in a scintillation counter using formula 989 as a scintillant. The number of bound cells was calculated based on specific labeling of each cell line. Antibodies HPDG2/3 (anti-P-selectin; neutralizing), HPDGZ/l (anti-P-selectin; non-neutralizing), HEL 3/ 2 (anti-E-selectin; neutralizing), and HEL4/1 (anti-E-selectin; non-neutralizing) were used at a concentration of 10 pg/mL. As a control, human IgG 110 pg/mL) was captured instead of selectin chimeras.
This result is consistent with FACS analysis using PSL275, which showed that similar amounts of PSGL-I are expressed on the cell surface of both cell lines. No other major bands were observed in either immunoprecipitation. PSGL-1 could be affinity-captured with immobilized P-selectin from 3.4B + C2, but not from 3.4B, cells (Fig 3, lane 2) . This Pselectin-bound material could be reimmunoprecipitated with anti-P-selectin Rb3443 (lane 3 ) showing that PSGL-I is the principal molecule in 3.4B + C2 cells that bound to P-selectin. These data indicate that core2-modified PSGL-I binds to P-selectin with high-affinity.
Riochemical evidence that transfection with core2 mod-$es the 0-glycans qf PSGL-1. To show that core2 had a direct effect on PSGL-1 oligosaccharides, 0-glycans were liberated by hydrazinolysis from PSGL-I purified from 'Hglucosamine-labeled cells and evaluated by gel filtration chromatography. Figure 4B shows that the 0-linked glycans isolated from PSGL-I produced in 3.4B cells are simple structures, as evidenced from two major peaks coeluting with the disaccharide Gal@ 1-3 GalNAc and the monosaccharide GalNAc. These products are consistent with those produced on desialyation of core1 structures. No higher molecular weight species were observed. The 0-linked glycans of PSGL-I produced in 3.4B + C2 cells show higher molecular weight species corresponding to trisaccharide or greater products, thus suggesting that core2 transfection produced more elaborated 0-linked glycans. For comparison, 0-linked oligosaccharides from CD43, which is known to carry core2-modified 0-glycans,'" are shown in Fig 4A. 
DISCUSSION
Previous studies have shown that SLeX or related carbohydrate structures on PSGL-I are important determinants for high-affinity binding to P-selectin.'.'x By FACS analysis, PSGL-I produced in CHO cells expressing Fuc-TI11 (3.4B) failed to show any significant binding to P-selectin as compared with that for the human myelocytic cell line U937.
Moreover, no PSGL-1 could be affinity-captured with immobilized P-selectin from 3.4B cell line in spite of the fact that expression of PSGL-1 and SLeX on the surface of 3.4B cells is comparable with or better than that of U937 cells. These observations contrast with those obtained using PSGL-1 derived from neutrophils, U937 cells, or COS cells expressing Fuc-TIII.'.'.~ These differences were attributed to cell-specific differences in posttranslational modification. When core2 [p( 1.6) GlcNAc transferase], a key O-glycanbranching enzyme, was coexpressed in 3.4B cells, the resulting cell line (3.4B + C2) expressed PSGL-I capable of mediating high-affinity binding to P-selectin. This result is evidenced by the fact that PSGL-I from 3.4B + C2 cells could be affinity-captured by P-selectin. In addition. substantially greater binding of 3.4B + C2 cells to P-selectin was observed in a plate assay using immobilized P-selectin or in FACS analysis.
The expression of core2 did not significantly alter cell surface levels of PSGL-1 and SLeX, as determined by FACS staining with MoAb PSL275 and CSLEX-I , respectively. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Affinity-capture experiments showed that PSGL-1 remains the sole high-affinity counterreceptor for P-selectin in the core2-expressing cell line, as evidenced by the ability of anti-PSGL-1 Rb3443 to recapture P-selectin-bound material. Analysis of the 0-linked glycans of PSGL-1 indicates that coexpression of core2 transferase results in more elaborated oligosaccharides as compared with those obtained from PSGL-I in the absence of core2 transferase. Thus, concomitant expression of fucosyltransferase and core2 results in an alteration of PSGL-I 0-glycans that directly correlates with the ability to bind to P-selectin. Recently, Li et alZh have also reported on the crucial role of core2 in biosynthesis of functional PSGL-1. In general, these investigators arrived at conclusions similar to those presented here. Our results extend these observations by showing that high-affinity binding of PSGL-1 to P-selectin requires core2 activity.
Expression of core2 did not result in any increased binding that CHO cells containing a fucosyltransferase capable of synthesizing SLe" all support E-selectin binding, we can only assume that this discrepancy is attributable to different experimental conditions. The results of recent ~tudies'"'~ have reported that a 19-amino-acid region at the amino terminus of mature (PACEcleaved) PSGL-1 is sufficient to mediate high-affinity binding to P-selectin and contains both a protein recognition site (tyrosine sulfation) and a carbohydrate determinant. The oligosaccharide component is presented by a single 0-linked glycosylation site at position 16 threonine (T16). Mutation of this single residue abolishes binding to P-selectin suggesting that glycosylation at this single site, T16, is necessary and sufficient for P-selectin binding. Thus, it will be interesting to determine the exact glycan structures present on T16 in PSGL-1. Detailed analysis of glycans of PSGL-I will enhance our understanding of molecular basis of high-affinity binding of PSGL-1 to P-and E-selectins.
